Myasthenia Gravis

Latest News

Cell and gene therapies | Image Credit: © ArtemisDiana-stock.adobe.com
RNA CAR T Shows Promise for Myasthenia Gravis

September 3rd 2025

Long-term follow-up data on the use of BCMA-directed RNA chimeric antigen receptor T-cell therapy (CAR T) for refractory generalized myasthenia gravis show patient outcomes at 2, 3, 6, 9, and 12 months.

Myasthenia Gravis | Image Credit: © lexiconimages-stock.adobe.com
ADAPT SERON Trial Shows Positive Results for Seronegative gMG

August 28th 2025

glucocorticoid | Image Credit: © Vitalii Vodolazskyi-stock.adobe.com
Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation

August 25th 2025

myasthenia gravis on a chalkboard | Image Credit: © Yurii Kibalnik-stock.adobe.com
MG Symptoms PRO Highlights Rozanolixizumab’s Impact on Fatigue, Weakness

August 22nd 2025

Myasthenia Gravis | Image Credit: © designua - stock.adobe.com
Nomogram Aids Early Detection of Myasthenic Crisis Risk

August 19th 2025

More News

A woman's vibrant hair dye may have triggered myasthenic crises, a case study found. | Image credit: LIGHTFIELD STUDIOS - stock.adobe.com
June 29th 2024

Case Study: Hair Dye Containing MIT Precipitates Myasthenic Crises

Gayle Turim Dickstein
A 43-year-old woman had 2 myasthenic crises within 3 months, with both taking place shortly after exposure to hair dye containing methylisothiazolinone (MIT).
Girl and female doctor | Image Credit: © Studio Romantic - stock.adobe.com
June 26th 2024

Thymectomy in Children With Myasthenia Gravis: An Option to Consider

Gayle Turim Dickstein
Results of a recent database analysis reveal that patients with juvenile myasthenia gravis—particularly prepubescent girls—might benefit from early thymectomy to cut production of autoreactive AChR B cells. Usually, though, it’s not done.
Teenage boy meeting with a doctor | Image credit: Monkey Business - stock.adobe.com
June 18th 2024

Eculizumab Shows Promising Results in Adolescents With Myasthenia Gravis

Kimberly Rath, PharmD
Study findings show eculizumab is effective and well tolerated in reducing disease burden in adolescents with refractory anti-acetylcholine receptor antibody–positive generalized myasthenia gravis.
Myasthenia gravis word photo | Image Credit: © Andrii - stock.adobe.com
June 12th 2024

Case Highlights Difficulties Identifying MG Secondary to ICI Therapy

Jared Kaltwasser
There currently are no guidelines on how to treat this patient group, despite a high risk of mortality.
Older woman eye | Image Credit: © Syda Productions - stock.adobe.com
June 8th 2024

Patient With MG-Related Ptosis Successfully Treated With Nasal Spray Duo

AJMC Contributor
Although further research is needed, these new findings suggest that using the 2 intranasal sprays is an effective option for patients with myasthenia gravis (MG) who experience eyelid drooping.
Pediatrician test results tablet parent child - nimito - stock.adobe.com.jpeg
June 6th 2024

New Data May Help Guide Optimization of Pediatric MG Treatment Duration

AJMC Contributor
Researchers say their findings will help inform treatment protocols for this patient population, as questions remain about optimal duration of these treatments following first-line treatment with pyridostigmine.
Depressed teen girl with smartphone | Image Credit: © New Africa - stock.adobe.com
May 29th 2024

Case Report Finds SSRIs Work Alongside MG Therapy in Teen Patient

Jared Kaltwasser
The report found a selective serotonin reuptake inhibitor (SSRI) did not offset the effects of myasthenia gravis (MG) medication.
Health care medical icon | Image Credit: Deemerwha studio-stock.adobe.com
May 26th 2024

Group Provides Best Practices for Preventing Myasthenic Crisis Following Thymectomy

AJMC Contributor
Myasthenic crisis has been estimated to occur in up to 30% of patients with myasthenia gravis after thymectomy.
Senior man | Image Credit: sebra-stock.adobe.com
May 22nd 2024

Case Report: Abducens Nerve Palsy Could Be Sign of Myasthenia Gravis

Jared Kaltwasser
A 68-year-old man was diagnosed with ocular myasthenia gravis after presenting with double-vision and photophobia.
Myasthenia gravis word photo | Image Credit: Andrii-stock.adobe.com
Published: May 15th 2024 | Updated: May 15th 2024

Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants

AJMC Contributor
Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Myasthenia Gravis | Image Credit: luchschenF-stock.adobe.com
May 13th 2024

Case Report: Upper Extremity DVT in Patient With Seronegative MG

AJMC Contributor
In addition to her advanced age and obesity status, the patient had a history of pulmonary embolism managed with an inferior vena cava filter, increasing her risk of thrombosis.
Concept of Myasthenia Gravis | Image Credit: © syahrir - stock.adobe.com
May 1st 2024

Extension Trial Shows Zilucoplan Safe and Effective for MG at 60 Weeks

Jared Kaltwasser
COVID-19 and worsening myasthenia gravis (MG) were the most common treatment-emergent adverse events, the study found.
Diagnosis myasthenia gravis | Image Credit: Николай Зотов - stock.adobe.com
April 27th 2024

UK Study: Most Patients With MG Require Hospitalization, Driving Health Care Resource Use

AJMC Contributor
Over a median follow-up time of nearly 3 years, three-fourths (72.8%) of patients with myasthenia gravis (MG) were hospitalized and half visited the accident and emergency department.
Case study graphic | Image Credit: STOATPHOTO - stock.adobe.com
April 19th 2024

Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome

Luke Halpern
A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Myasthenia gravis photo | Image Credit: syahrir - stock.adobe.com
April 15th 2024

Long-Term Data Affirm Efficacy of Eculizumab in Refractory Generalized MG

Jared Kaltwasser
A new survey has found that most patients who have generalized myasthenia gravis who switched from eculizumab to ravulizumab preferred the latter.
term myasthenia gravis | Image Credit: lexiconimages - stock.adobe.com
April 11th 2024

Bioinformatics, Machine Learning Reveal New Insights Into MG-Associated DCM

AJMC Contributor
Researchers explain that these insights have important implications, if validated in further research, as challenges with early detection of dilated cardiomyopathy complicate myasthenia gravis (MG)-prognosis.
Myasthenia gravis | Image Credit: Andrii - stock.adobe.com
April 6th 2024

Online Discussions Illuminate Daily Challenges, Treatment Hurdles in MG

AJMC Contributor
Analyzing trends from online conversations among patients with myasthenia gravis (MG), researchers found that issues with current treatments were mentioned in nearly 24% of conversations.
myasthenia gravis | Image Credit: luchschenF - stock.adobe.com
March 28th 2024

Patients With Autoimmune Thyroid Disease at Higher Risk of Myasthenia Gravis

AJMC Contributor
These insights, explain the researchers of the study, complement observational studies, which have previously indicated a causal relationship between the 2 diseases.
Myasthenia Gravis with phrase on the page | Image Credit: Yurii Kibalnik - stock.adobe.com
March 23rd 2024

Researchers Highlight Current Gaps in Research on Exercise Use in MG

AJMC Contributor
The researchers note that their findings can help inform adjustments for future research among individuals living with myasthenia gravis (MG).
Myasthenia gravis stock image | Image Credit: lhphotos - stock.adobe.com
March 21st 2024

Pilot Study Links Possible Lab Markers With Risk of Myasthenic Crisis

AJMC Contributor
These findings, together with real-world data, could help inform risk classification of myasthenic crisis beyond known risk factors, such as infection.
Older man and doctor on telehealth visit | Image Credit: fizkes - stock.adobe.com
March 13th 2024

Rising Myasthenia Gravis Rates in Older US Men Spark Research, Public Health Concerns

Gwen Mergian
Incidence and prevalence of myasthenia gravis in the US has increased surprisingly since last examined more than 20 years ago.
Concept of Myasthenia Gravis writing on sticky notes isolated on Wooden Table | Image credit: syahrir - stock.adobe.com
March 8th 2024

Review: Vigilance Warranted to Prevent, Treat Transient Neonatal Myasthenia Gravis

Jared Kaltwasser
Preventive measures can reduce the risk to newborns, but careful monitoring is necessary, the authors said.
Conceptual photo about Myasthenia Gravis | Image credit: Yurii Kibalnik-stock.adobe.com.jpeg
March 5th 2024

Batoclimab Outperforms Placebo in Phase 3 Generalized MG Trial

Jared Kaltwasser
The fully humanized monoclonal antibody led to results among patients with generalized myasthenia gravis (MG) similar to that of efgartigimod, the authors said.
Gut microbiome - sdecoret - stock.adobe.com
February 29th 2024

Analysis Identifies Gut Microbiota Affecting Risk of MG

AJMC Contributor
The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an increased of or protective effect against MG.
Graphical representation of autoantibody diseases | Image credit: lexiconimages - stock.adobe.com
February 29th 2024

Intravenous Nipocalimab Infusions Safe, Effective Against Autoantibody-Mediated Diseases

Luke Halpern
After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter treatment periods and with larger doses.
Myasthenia gravis | Image credit: Andrii - stock.adobe.com
February 22nd 2024

Phase 2 Results Show Safety, Dose-Dependent Improvements in Function With Nipocalimab in gMG

AJMC Contributor
Based on data from the study, a phase 3 confirmatory trial is underway for the humanized monoclonal antibody.
Myasthenia gravis report | Image credit: mdaros - stock.adobe.com
February 15th 2024

Vyvgart Phase 3 Extension Study Data Affirm Long-Term Safety, Efficacy in gMG

AJMC Staff
Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune disease.
MYASTHENIA GRAVIS inscription on the black board Image credit: Yurii Kibalnik - stock.adobe.com
February 9th 2024

Phase 3 Trial Will Assess Whether Humanized mAb Addresses Patient Needs in MG

AJMC Staff
Dubbed the FLEX trial, the study will explore whether batoclimab will address important patient needs throughout different phases of the myasthenia gravis (MG).
Myasthenia Gravis illustration isolated on red background | Image credit: lhphotos - stock.adobe.com
February 6th 2024

Possible Increase in Prevalence of Alzheimer Disease Found in Patients With Myasthenia Gravis

Luke Halpern
Investigators observed an increase in the prevalence of Alzheimer disease in patients with diagnosed myasthenia gravis (MG), which indicates that MG is an independent risk factor for AD.
Myasthenia gravis | Image credit: lexiconimages - stock.adobe.com
January 31st 2024

IV Methylprednisolone, Tacrolimus Effective in Prednisone-Resistant Ocular MG

AJMC Staff
Researchers have retrospectively analyzed data from nearly 60 patients with ocular myasthenia gravis (MG) not adequately responding to oral prednisone, finding that both intravenous (IV) methylprednisolone and tacrolimus monotherapy helped reduce symptoms.
<1234567>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo